Close Menu

More articles about Genomics: Clinical Implementation

Genentech will use Adaptive's ClonoSeq assay for MRD testing in a CLL study. Adaptive will receive upfront and sample testing payments of undisclosed amounts.

In seven years, the public variant classification database has steadily become a resource that labs are submitting to and that genetics experts are consulting.

The multi-center registry study aims to measure the clinical impact of serial testing with Signatera in patients with stage II or stage III colorectal cancer.

The legislation is intended to allow states to conduct whole-genome sequencing on children on Medicaid who have a disease with a suspected genetic cause.

Despite the availability of more precision therapies and complex biomarker tests, systemic gaps and lack of physician education continued to hinder access.

Simulations suggested prostate cancer screening informed by polygenic risk scores is more cost effective and less prone to overdiagnoses than screening based on age alone.

Foundation Medicine's ctDNA assay was able to subclassify patients into higher and lower recurrence risk groups with CTCs providing an additional boost.

The researchers used the Guardant360 assay and droplet digital PCR to identify genetic mutations in circulating tumor DNA that had been shed into the patients' bloodstream.

Absent sufficient evidence to support genetic testing for all patients, the group recommended following existing guidelines, which are based on clinical factors.

Researchers at Baylor College of Medicine and Columbia University found that almost all blood samples from pregnant women tested contained several trophoblasts.

In a proof-of-principle study, Ohio State University researchers compared the nanopore sequencing assay to short-read sequencing and capillary electrophoresis.

The team will present the results to the US Food and Drug Administration as part of a 510(k) application in order to commercialize the technology with Biofluidica.

The guidelines place a stronger emphasis on pancreatic cancer risk genes, and broaden testing recommendations for those with Ashkenazi Jewish ancestry.

A survey by University of Nebraska researchers found that both specialists and primary care healthcare providers largely interpreted genetic testing results correctly.

Investigators compared expression in different men across the genes from three commercial panels, arguing that the findings highlight important unknowns.

Despite the step-up in FDA action against labs offering PGx tests, the success of these programs suggests that access to them isn't being stifled as some feared.

This report contains a quantitative, evidence-based scoring framework to help guide the evaluation of constitutional CNVs across clinical labs.

In a survey conducted by an association working group, 40 percent of respondents said they are already offering TMB, with most others planning to do the same within the year.

A preliminary analysis lends some support to covering NIPS for pregnancies beyond high-risk, and some payors have expanded coverage.  

 

Invitae is providing the testing services as part of the 12-month pilot, while patients will have the option to share their results with researchers though LunaDNA.

Pages